Celcuity's experimental breast cancer combination therapy achieved its primary endpoints in a Phase 3 trial, setting the stage for an FDA filing anticipated in Q4. The trial results position Celcuity’s drug to challenge established treatments by Novartis and Roche. This advancement marks a significant milestone for the small biotech in the competitive oncology space, potentially improving mortality outcomes for specific patient subsets.